| Molecular diversity of midbrain development in mouse, human, and stem cells G La Manno, D Gyllborg, S Codeluppi, K Nishimura, C Salto, A Zeisel, ... Cell 167 (2), 566-580. e19, 2016 | 844 | 2016 |
| Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion JM Nygren, K Liuba, M Breitbach, S Stott, L Thorén, W Roell, C Geisen, ... Nature cell biology 10 (5), 584-592, 2008 | 201 | 2008 |
| Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis L Roybon, T Hjalt, S Stott, F Guillemot, JY Li, P Brundin PloS one 4 (3), e4779, 2009 | 191 | 2009 |
| Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of P arkinson's disease SRW Stott, RA Barker European Journal of Neuroscience 39 (6), 1042-1056, 2014 | 155 | 2014 |
| Parkinson’s disease drug therapies in the clinical trial pipeline: 2020 K McFarthing, S Buff, G Rafaloff, T Dominey, RK Wyse, SRW Stott Journal of Parkinson's disease 10 (3), 757-774, 2020 | 142 | 2020 |
| GDNF and Parkinson’s disease: where next? A summary from a recent workshop RA Barker, A Björklund, DM Gash, A Whone, A Van Laar, JH Kordower, ... Journal of Parkinson's disease 10 (3), 875-891, 2020 | 121 | 2020 |
| In vitro characterization of a human neural progenitor cell coexpressing SSEA4 and CD133 P Barraud, S Stott, K Møllgård, M Parmar, A Björklund Journal of neuroscience research 85 (2), 250-259, 2007 | 118 | 2007 |
| A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease JC Villaescusa, B Li, EM Toledo, PIA Rivetti di Val Cervo, S Yang, ... The EMBO journal 35 (18), 1963-1978, 2016 | 113 | 2016 |
| Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages SRW Stott, E Metzakopian, W Lin, KH Kaestner, R Hen, SL Ang Journal of Neuroscience 33 (18), 8022-8034, 2013 | 105 | 2013 |
| Trial of lixisenatide in early Parkinson’s disease WG Meissner, P Remy, C Giordana, D Maltête, P Derkinderen, JL Houéto, ... New England Journal of Medicine 390 (13), 1176-1185, 2024 | 102 | 2024 |
| Neuroprotective effect of TREM-2 in aging and Alzheimer’s disease model AA Raha, JW Henderson, SRW Stott, R Vuono, S Foscarin, RP Friedland, ... Journal of Alzheimer's Disease 55 (1), 199-217, 2017 | 99 | 2017 |
| Parkinson’s disease drug therapies in the clinical trial pipeline: 2022 update K McFarthing, G Rafaloff, M Baptista, L Mursaleen, R Fuest, RK Wyse, ... Journal of Parkinson's disease 12 (4), 1073-1082, 2022 | 95 | 2022 |
| Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease JJ Kim, D Vitale, DV Otani, MM Lian, K Heilbron, H Iwaki, J Lake, ... Nature genetics 56 (1), 27-36, 2024 | 84 | 2024 |
| Dopamine and Huntington’s disease LC Schwab, SN Garas, J Drouin-Ouellet, SL Mason, SR Stott, RA Barker Expert review of neurotherapeutics 15 (4), 445-458, 2015 | 82 | 2015 |
| Expression and cellular localization of hepcidin mRNA and protein in normal rat brain R Raha-Chowdhury, AA Raha, S Forostyak, JW Zhao, SRW Stott, ... Bmc Neuroscience 16, 1-13, 2015 | 80 | 2015 |
| Parkinson’s disease drug therapies in the clinical trial pipeline: 2023 update K McFarthing, S Buff, G Rafaloff, B Fiske, L Mursaleen, R Fuest, RK Wyse, ... Journal of Parkinson's Disease 13 (4), 427-439, 2023 | 67 | 2023 |
| Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study M Rizig, S Bandres-Ciga, MB Makarious, OO Ojo, PW Crea, OV Abiodun, ... The Lancet Neurology 22 (11), 1015-1025, 2023 | 65 | 2023 |
| Parkinson’s disease drug therapies in the clinical trial pipeline: 2021 update K McFarthing, G Rafaloff, MAS Baptista, RK Wyse, SRW Stott Journal of Parkinson's disease 11 (3), 891-903, 2021 | 65 | 2021 |
| Dopamine neuron precursors within the developing human mesencephalon show radial glial characteristics JB Hebsgaard, J Nelander, H Sabelström, ME Jönsson, S Stott, M Parmar Glia 57 (15), 1648-1659, 2009 | 49 | 2009 |
| N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats R Krishnamurthi, S Stott, M Maingay, RLM Faull, D McCarthy, P Gluckman, ... Neuroreport 15 (10), 1601-1604, 2004 | 48 | 2004 |
